Core Insights - NovaBridge Biosciences is conducting a business update call to discuss the clinical data and development plan for its pipeline asset VIS-101 [2][3] Group 1: Company Overview - NovaBridge operates under a hub-and-spoke business model, with the first spoke company being Visara, which focuses on ophthalmology [3] Group 2: Clinical Data and Development Plan - The presentation will include details on the Phase IIa clinical data for VIS-101, the first pipeline asset of Visara [3] - The company will also provide insights from key opinion leaders (KOLs) regarding the clinical development plan for VIS-101 [3]